stockrowBruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024.
- Revenue
- +1.57%
- EPS
- −75.4%
- Free cash flow
- +278.7%
- Total debt
- −14.7%
Quarter to September 2026, against a year earlier
Follow BRKR
Alert me
Bruker Corporation (BRKR) EPS (diluted)
Bruker Corporation's EPS (diluted) for fiscal 2025 was −$0.15, compared with $0.76 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$1.01. Over the past ten years it has ranged from −$0.15 (fiscal 2025) to $2.90 (fiscal 2023) — the current reading is the lowest in ten years. Bruker Corporation ranks 84th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.15 | — |
| FY2024 | $0.76 | (73.79%) |
| FY2023 | $2.90 | 45.73% |
| FY2022 | $1.99 | 9.94% |
| FY2021 | $1.81 | 77.45% |
| FY2020 | $1.02 | (19.05%) |
| FY2019 | $1.26 | 10.53% |
| FY2018 | $1.14 | 132.65% |
| FY2017 | $0.49 | (48.42%) |
| FY2016 | $0.95 | 58.33% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.72 | — |
| Jun 2026 | −$0.41 | — |
| Mar 2026 | $0.02 | (80.00%) |
| Dec 2025 | $0.10 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $37.97 |
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| PODD Insulet Corporation compare | $6.14 |
| GMED Globus Medical, Inc. compare | $4.07 |
| PEN Penumbra, Inc. compare | $3.97 |
| SNN Smith & Nephew SNATS, Inc. compare | $1.13 |
| TXG 10x Genomics compare | −$0.59 |
| BRKR Bruker Corporation | −$1.01 |
| GKOS Glaukos Corporation compare | −$2.94 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BRKR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement